Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

[1]  D. Planchard,et al.  Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Soo,et al.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer , 2018, Targeted Oncology.

[3]  Y. Ohe,et al.  128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes , 2018 .

[4]  S. Novello,et al.  139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) , 2018 .

[5]  B. Goh,et al.  Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.

[6]  S. Um,et al.  First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. , 2018, Annals of Translational Medicine.

[7]  V. Hirsh.  Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors , 2018, Therapeutic advances in medical oncology.

[8]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[9]  E. Cho,et al.  CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Liam.  Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer. , 2017, Translational lung cancer research.

[11]  Thomas John,et al.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yvette N. Lamb,et al.  Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer , 2017, Targeted Oncology.

[13]  G. O’Kane,et al.  Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer , 2017, Front. Oncol..

[14]  Keunchil Park,et al.  Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? , 2017, Current opinion in oncology.

[15]  Shuhang Wang,et al.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors , 2016, Frontiers of Medicine.

[16]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[17]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Cho,et al.  CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  T. Bolin,et al.  OF HEALTH , 2022 .